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Assembly of a scaffold consisting of CARD9, BCL10,
and MALT1 (CBM complex) is critical for effective
signaling by multiple pattern recognition receptors
(PRRs) including Dectin and RIG-I. The RUN domain
Beclin-1-interacting cysteine-rich-containing Rubi-
con protein associates constitutively with the
Beclin-UVRAG-Vps34 complex under normal condi-
tions to regulate autophagy. Rubicon also interacts
with the phagocytic NADPH-oxidase complex upon
TLR stimulation to induce potent antimicrobial
responses. Here, we showRubicon is a physiological
feedback inhibitor of CBM-mediated PRR signaling,
preventing unbalanced proinflammatory responses.
Upon Dectin-1- or RIG-I-mediated activation, Rubi-
con dynamically exchanges binding partners from
14-3-3b to CARD9 in a stimulation-specific and
phosphorylation-dependent manner, disassembling
the CBM signaling complex and ultimately termi-
nating PRR-induced cytokine production. Remark-
ably, Rubicon’s actions in the autophagy complex,
phagocytosis complex, and CBM complex are func-
tionally and genetically separable. Rubicon thus
differentially targets signaling complexes, depend-
ing on environmental stimuli, and may function to
coordinate various immune responses against
microbial infection.
INTRODUCTION
The first step to mounting a protective immune response is the
recognition of pathogens by cell surface receptors, called
pattern recognition receptors (PRRs), located on professional
phagocytes, dendritic cells, and nonimmune cells (KumarCell Hoet al., 2011; Palm and Medzhitov, 2009). PRRs include C-type
lectin receptors, transmembrane Toll-like receptors (TLRs),
NOD-like receptors (NLRs), and cytoplasmic RIG-I-like helicases
(RLHs). After recognizing specific pathogen-associated molec-
ular patterns, PRRs activate intracellular signaling pathways
and stimulate inflammatory mediators. This triggers effector
immune mechanisms (Puel et al., 2010), ultimately resulting in
the elimination of the pathogen from the infected host. However,
unbalanced, continuous production of inflammatory cytokines
could lead to deleterious effects on host immunity such as
autoimmune diseases. Not surprisingly, PRR-mediated innate
immune responses are tightly regulated by several mechanisms,
including PRR modification and degradation (Arimoto et al.,
2007) or the expression of dominant-negative or alternatively
spliced variants of PRRs and their downstreammolecules (Jans-
sens et al., 2002; Leung et al., 2007; Rosenstiel et al., 2006).
C-type lectin PRRs like Dectin, DC-SIGN, and mannose
receptor interact with pathogens primarily through the recogni-
tion of distinct carbohydrates, such as mannose, fucose, or
glucan structures (Drummond et al., 2011; Hara and Saito,
2009; Kerrigan and Brown, 2010; Reid et al., 2009; Ruland,
2008). Recognition by C-type lectins is important for the internal-
ization of pathogens, which leads to the induction of intracellular
signaling cascades to direct immune responses. Dectin-1 is a
unique C-type lectin that recognizes b-glucan carbohydrates
on various fungi, including Candida (C) albicans, and its activa-
tion induces both Th1 and Th17 immune responses that are
essential for antifungal defenses (Drummond et al., 2011; Hara
and Saito, 2009; Ruland, 2008). Engagement of Dectin-1 by
fungal b-glucans leads to phosphorylation of the immunorecep-
tor tyrosine-based activation motif (ITAM)-like sequence within
its cytoplasmic domain, and subsequent association of the Syk
tyrosine kinase induces the assembly of a scaffold consisting
of caspase recruitment domain 9 (CARD9), B cell lymphoma
10 (BCL10), and mucosa-associated lymphoid tissue lymphoma
translocation gene 1 (MALT1) (Hara and Saito, 2009). On the
other hand, Dectin-2 interacts with C. albicans through mannan
structures present on both its yeast and hyphal forms (Bi et al.,st & Microbe 11, 277–289, March 15, 2012 ª2012 Elsevier Inc. 277
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associating with the FcRg chain, and ultimately results in
CARD9-dependent signal transduction (Drummond et al.,
2011; Gringhuis et al., 2011; Saijo et al., 2010). Thus, Dectin
constitutes a major fungal PRR that can couple to the Syk-
CARD9 innate signaling pathway to activate monocyte lineage
immune cells and regulate adaptive immune responses to fungal
infections.
Two CARD-containing adaptor molecules, CARMA1 (CARD-
containing MAGUK protein 1) and CARD9, play critical roles
in the activation and regulation of both innate and adaptive
immunity (Blonska and Lin, 2011; Hara and Saito, 2009).
CARMA1 and CARD9 regulate the cell-type-specific activation
of BCL10-MALT1-mediated activation of NF-kB and MAPK in
lymphoid cells (e.g., T cells, B cells, and natural killer cells) and
myeloid cells (e.g., macrophages and dendritic cells), respec-
tively, called lymphoid-type CARMA1-BCL10-MALT1 (L-CBM)
and myeloid-type CARD9-BCL10-MALT1 (M-CBM) (Hara and
Saito, 2009). Myeloid CBM is essential in antifungal immunity
and is implicated in mediating Dectin-Syk-induced NF-kB
activation in response to C. albicans infection. Biochemical
and genetic experiments demonstrate that the CBM signaling
module mediates Dectin signaling for the activation of NF-kB
and MAPK pathways (Blonska and Lin, 2011). In fact, dendritic
cells and macrophages deficient in CARD9, BCL10, or MALT1
consistently show severe defects in pathogen-induced NF-kB
activation and cytokine production, indicating that the CBM
signaling module is key for antimicrobial innate immunity in
myeloid cells. Furthermore, the CBM module is an essential
component of RIG-I- and NLR-dependent proinflammatory
responses (Gross et al., 2006; Poeck et al., 2010), and CARD9
also associates with the GDP-dissociation inhibitor LyGDI in
phagosomes after bacterial and fungal infection (Underhill and
Shimada, 2007; Wu et al., 2009), leading to reactive oxygen
species (ROS) production and bacterial killing in macrophages.
Thus, CARD9 is a key signaling molecule for efficient host
microbe-elicited innate immunity.
Rubicon (RUN domain Beclin-1-interacting cysteine-rich-
containing) was recently identified as a Beclin-1-binding partner
that localizes to the late endosome/lysosome, and negatively
regulates the maturation step of autophagy and the endocytic
pathway (Matsunaga et al., 2009; Zhong et al., 2009). While
Rubicon primarily associates with the Beclin-1-containing
autophagy complex under normal and stressed conditions, we
recently reported that Rubicon is also an essential positive
regulator of the NADPH oxidase complex, (Yang et al., 2012
[accompanying paper, this issue of Cell Host & Microbe]).
Upon microbial infection or TLR activation, Rubicon transiently
interacts with p22phox of the NADPH oxidase complex to induce
a potent antimicrobial burst of ROS and inflammatory cytokines
(Yang et al., 2012). Thus, Rubicon regulates both autophagy and
phagocytosis, depending on the environmental stimulus, and is
perfectly positioned to coordinate different but related innate
immune mechanisms in a phagocytic cell.
Most biological processes require both positive and negative
regulatory mechanisms to maintain equilibrium. While the PRR
pathway robustly induces host immune responses upon micro-
bial infection, it must slow down and ultimately stop when it
reaches a late stage to avoid excessive production of inflamma-278 Cell Host & Microbe 11, 277–289, March 15, 2012 ª2012 Elsevietory cytokines, which could lead to deleterious effects on host
immunity. Here we show that Rubicon differentially binds to
14-3-3b and CARD9 in a stimulation-specific, phosphorylation-
dependent, and competitive manner, resulting in the disas-
sembly and elimination of CBM complex signaling. Thus, Rubi-
con acts as a physiological brake for CBM-mediated immune
responses, serving as an inhibitory feedback mechanism.
RESULTS
Temporal Interactions of Rubicon with 14-3-3b
and CARD9
Rubicon contains a RUN domain, an N-terminal serine-rich
region (SR-N), a coiled-coil domain (CCD), a C-terminal serine-
rich region (SR-C), a helix-coil-rich region (H-C), and a
cysteine-rich region (C-R) (Figure 1A). A yeast two-hybrid screen
of the full length, the N-terminal region (aa 1–505), and the
C-terminal region (aa 506–972) of Rubicon collectively revealed
that Rubicon interacts with 14-3-3b and CARD9 through its
N-terminal and C-terminal regions, respectively. Coimmunopre-
cipitation (coIP) showed that Rubicon interacted with endoge-
nous 14-3-3b through its SR-N region (Figure 1B). The highly
conserved 14-3-3 family members are phosphoserine/phospho-
threonine binding proteins, and their high-affinity binding motifs
are RSXpSXP (mode-1) and RXXXpSXP (mode-2), where pS and
X represent phosphoserine and any amino acid, respectively
(Morrison, 2009). A large-scale proteomics analysis of the human
kinome (Oppermann et al., 2009) has shown that Rubicon
undergoes multiple phosphorylations including the S248 residue
within its SR-N region whose surrounding sequences
(RSTpS248FP) fit very well with the mode-1 binding motif of
14-3-3. Indeed, the specific deletion (DSR-N) or point mutation
(S248A) of Rubicon completely abolished its interaction with
14-3-3b, suggesting that this interaction appears to be S248-
phosphorylation dependent (Figures 1B and 1C).
Besides 14-3-3b binding, Rubicon also showed a robust inter-
action with CARD9: either the N-terminal CARD or the central
CCD of CARD9 was sufficient to bind to Rubicon, and the
C-terminal region of Rubicon is responsible for CARD9 binding
(Figures 1D–1F). Computational sequence analysis predicted
three helix-coiled repeats (HC1, aa 625–671; HC2, aa 672–709;
and HC3, aa 710–760) within the Rubicon C-terminal region. A
detailed mapping study using various mammalian glutathionine
S-transferase (GST)-Rubicon fusions indicates that while each
HC motif of Rubicon exhibited only a minimal binding affinity to
CARD9, the GST-Rub-HC123 fusion carrying all three HCmotifs
bound CARD9 as strongly as GST-Rub-C carrying the
C-terminal region (Figure 1F). These results indicate that
Rubicon independently interacts with 14-3-3b and CARD9
through its N-terminal SR-N region and C-terminal HC region,
respectively.
Dynamic Competition between 14-3-3b and CARD9
for Rubicon Binding
Under normal conditions, Rubicon efficiently interacted with
endogenous 14-3-3b, whereas an interaction with endogenous
CARD9 was not evident (Figure 1B). Furthermore, autophagy-
inducing rapamycin and phagocytosis-inducing zymosan stimu-
lations neither increased Rubicon’s interaction with endogenousr Inc.
Figure 1. Rubicon Interactions with 14-3-3b and CARD9
(A) Summary of the interactions of Rubicon WT and its mutants with Beclin-1, p22phox, 14-3-3b, and CARD9. The binding activities of Rubicon WT and mutants
are summarized based on the results of Figures 1B, 2A, and 2B and Figures S1A and S1B.
(B) Differential Rubicon interactions with 14-3-3b and CARD9. Raw264.7 cells containing vector, Flag-Rubicon WT, or its mutant were stimulated with or without
b-1,3-glucan for 30 min, followed by IP with aFlag and IB with a14-3-3b or aCARD9.
(C) S248A phosphorylation-dependent interaction of Rubicon with 14-3-3b. (Left) At 48 hr posttransfection with Flag-Rubicon WT or S248A mutant together with
V5-14-3-3b, 293T cells were used for IP with aV5 and IB with aFlag. (Right) At 48 hr posttransfection with Flag-RubiconWT or S248A mutant, Raw264.7 cells were
stimulated with or without b-1,3-glucan for 30 min, followed by IP with aFlag and IB with a14-3-3b.
(D) Summary of CARD9 interaction with Rubicon. (Top panel) Schematic diagram of CARD9. (Bottom panel) At 48 hr posttransfection with V5-CARD9 or its
deletion mutants together with Flag-Rubicon, 293T cells were used for IP with aFlag and IB with aV5.
(E) Rubicon-CARD9 interaction. At 48 hr posttransfection with V5-CARD9 and Flag-Rubicon, 293T cells were used for IP with aFlag and IB with aV5 or conversely
for IP with aV5 and IB with aFlag.
(F) Rubiconmapping for CARD9 interaction. (Left) At 48 hr posttransfectionwith V5-CARD9 andmammalianGST alone or GST fusions with Rubicon full length (F),
N terminus (N, aa 1–505), or C terminus (C, aa 506–972), 293T cells were used for GST-pull-down (PD) and IB with aV5. (Right) At 48 hr posttransfection with
V5-CARD9 and mammalian GST alone or various GST-Rubicon fusions, 293T cells were used for GST-PD and IB with aV5. See also Figure S1.
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14-3-3b (see Figures S1A and S1B available online). Since
CARD9 plays a major role in the b-1,3-glucan-mediated activa-
tion of Dectin-1 pathway in myeloid cells (Figure S1C), we stim-
ulated THP-1 cells containing Flag-Rubicon WT, DSR-N, S248A,
or DHCmutant with b-1,3-glucan and purified the Rubicon com-
plexes in a time course manner, followed by immunoblot with
the specific antibodies. These showed that Rubicon (130,000)
interacted with Vps15 (150,000), Vps34 (110,000), UVRAG
(85,000), and Beclin-1 (60,000) autophagy proteins, and
p22phox (22,000) and gp91phox (91,000) NADPH oxidase
proteins (Figures S2A and S2B). Notably, coIP showed that
Rubicon primarily interacted with 14-3-3b, but not CARD9, in
the absence of stimulation, but this interaction markedly
declined after 30 min of b-1,3-glucan stimulation concomitantlyCell Howith an increase in the interaction with CARD9, which then
declined after 120 min of stimulation (Figure S2B). The Rubicon
DSR-N and S248A mutants that no longer bind 14-3-3b main-
tained a constant interaction with CARD9 until late time points
after stimulation, whereas the Rubicon DHC mutant that no
longer binds CARD9 had a constant interaction with 14-3-3b,
indicating that the interactions of these mutants with CARD9
and 14-3-3b are thus independent of stimulation (Figure S2B).
Furthermore, pretreatment with anti-Dectin-1 blocking 2A11
antibody suppressed the Rubion-CARD9 interaction induced
by b-1,3-glucan stimulation, suggesting the signal-dependent
Rubicon-CARD9 interaction (Figure S1D).
To further delineate this dynamic competition between
14-3-3b and CARD9 for Rubicon binding, Flag-Rubicon com-
plexes were immunopurified upon b-1,3-glucan stimulationst & Microbe 11, 277–289, March 15, 2012 ª2012 Elsevier Inc. 279
Figure 2. Differential Interactions of Rubicon with 14-3-3b and CARD9
(A) Differential Rubicon interactions. Raw264.7 cells containing vector, Flag-Rubicon WT, or its mutant were stimulated with b-1,3-glucan for the indicated times,
followed by IP with aFlag and IB with aBeclin-1, aUVRAG, aCARD9, a14-3-3b, aBCL10, ap22phox, or aFlag. The results of vector control cells are shown in
Figure S4C, and the results of zymosan or rapamycin treatment are shown in Figures S1A and S1B.
(B) Differential CARD9 interactions upon b-1,3-glucan stimulation. Raw264.7 cells containing V5-CARD9 were stimulated with b-1,3-glucan for the indicated
times, followed by IP with aV5 and IB with aRubicon, aBCL10, ap22phox, or aV5.
(C and D) Differential CARD9 interactions. THP-1 cells were stimulated with b-1,3-glucan, zymosan depleted by hot alkali treatment, SeV infection, zymosan, or
BLP for 30 min, followed by IP with aCARD9 and IB with aRubicon, aBCL10, ap22phox, or aactin (C), or IP with aRubicon and IB with aCARD9, a14-3-3b,
ap22phox, or aactin (D).
(E) Competition between Rubicon and BCL10 for CARD9 interaction. At 48 hr posttransfection with V5-CARD9 or Flag-BCL10 together with increasing amounts
of AU1-Rubicon, 293T cells were used for IP with aV5 and IB with aFlag, aAU1, or aV5. See also Figure S2.
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between Rubicon and 14-3-3b was initially evident but dramati-
cally decreased after 30 min of b-1,3-glucan stimulation (Fig-
ure 2A and Figure S2C). In striking contrast, although Rubicon
interaction with CARD9 was undetectable during the initial
30 min of b-1,3-glucan stimulation, it robustly increased after
30–60min of stimulation and then declined thereafter (Figure 2A).
These features were binding specific: the DSR-N and S284A
mutants that lost 14-3-3b interaction continuously bound
CARD9 with no b-1,3-glucan stimulation, but their CARD9
binding ultimately declined after 60 min of stimulation, and the280 Cell Host & Microbe 11, 277–289, March 15, 2012 ª2012 ElsevieDHC mutant that lost CARD9 interaction constantly associated
with 14-3-3b regardless of b-1,3-glucan stimulation (Figure 2A).
However, all three mutants (DSR-N, S284A, and DHC) showed
similar Beclin-1 and p22phox binding kinetics to Rubicon WT,
whereas DCCD (Beclin-1 binding deficient) and DSR-C
(p22phox binding deficient) mutants showed similar 14-3-3b
and CARD9 binding kinetics to WT (Figure 2A, Figures S1A
and S1B). Importantly, these binding features and kinetics
were stimulation specific, as rapamycin or zymosan stimulation
did not lead to any detectable effects on 14-3-3b and CARD9
interactions (Figures S1A and S1B). These results collectivelyr Inc.
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ners from 14-3-3b to CARD9 in a specific-stimulation-depen-
dent, competitive manner.
Rubicon Interaction Disassembles the CBM Signaling
Complex
To examine the effect of Rubicon on the CBM complex, we puri-
fied radioactively labeled CARD9 complexes from mouse
Raw264.7 cells containing V5-CARD9 upon stimulation with
b-1,3-glucan and also performed the immunoblotting analysis
of purified CARD9 complexes. As previously shown (Blonska
and Lin, 2011; Hara and Saito, 2009; Ruland, 2008), CARD9
(65,000) was found to weakly associate with BCL10 (30,000)
without stimulation, with this interaction detectably increasing
at 15 min of b-1,3-glucan stimulation but decreasing thereafter
(Figure 2B and Figures S2D and S2E). Surprisingly, unlike the
CARD9-BCL10 interaction, the CARD9-Rubicon interaction
was initially minimal but markedly increased after 30–60 min of
b-1,3-glucan stimulation and declined afterward (Figure S2D).
Since CARD9 also mediates RIG-I signaling during viral infection
(Poeck et al., 2010), CARD9 complexes were immunopurified
from THP-1 and Raw264.7 cells upon stimulation with live
Sendai virus (SeV) infection for 30 min. Similar to stimulation
with b-1,3-glucan or zymosan depleted by hot alkali treatment,
SeV infection also induced the association of CARD9 with
Rubicon and the concomitant dissociation of CARD9 with
BCL10, whereas zymosan, bacterial lipoprotein (BLP), and
lipopolysaccharide (LPS) stimulation did not do so (Figures 2C
and 2D, Figures S2F and S2G). Finally, increasing levels of
Rubicon overexpression disrupted the interaction between
CARD9 and BCL10 in a dose-dependent manner, whereas this
b-1,3-glucan-induced disruption of CARD9-BCL10 interaction
was less pronounced upon the shRNA-mediated depletion of
endogenous Rubicon expression (Figure 2E, Figures S2H and
S2I). By striking contrast, Rubicon expression did not break
the interaction between CARD9 and LyGDI under the same
conditions (Figure S2J). These results show that CARD9 dynam-
ically changes binding partners from BCL10 to Rubicon in a
specific-stimulation-dependent manner, thus disassembling
the CARD9-BCL10 signaling complex.
Rubicon Has a Negative Effect on CBM-Mediated Signal
Transduction
Consistent with Rubicon’s ability to interact with CARD9 and
disassemble the CBM complex, expression of Rubicon WT,
DSR-N, or S284A mutant, but not DHC mutant, markedly sup-
pressed p38/JNK/IkB phosphorylation and IkB degradation in
Raw246.7 cells and mouse primary bone marrow-derived
dendritic cells (BMDCs) induced by b-1,3-glucan stimulation,
and NF-kB promoter activation in 293T cells; however, there
was no significant effect on the phosphorylation of p42/44
MAPK (Figure 3A, Figures S2K and S3A). To measure Rubicon’s
effect on CARD9-mediated ROS production, Raw264.7 or
primary mouse bone marrow-derived macrophage cells
(BMDMs) were infected with recombinant lentiviruses or adeno-
viruses for Rubicon expression or Rubicon depletion, followed
by stimulation with b-1,3-glucan, zymosan depleted by hot alkali
treatment, and heat-killed C. albicans or infection with SeV or
VSV. The resulting data demonstrate that neither RubiconCell Hoexpression nor Rubicon depletion affected ROS production
induced by various stimuli and infections (Figure 3B, Figures
S3B to S3D). Furthermore, Rubicon expression significantly
enhanced zymosan-induced ROS production in both wild-type
and CARD9/ BMDMs but showed nearly no effect on
C. albicans- or influenza A virus-induced ROS production under
the same conditions, consistent with the data showing Rubicon
has no effect on the CARD9-LyGDI interaction (Figure 3C and
Figures S3B–S3D). Finally, the loss of either 14-3-3b binding or
CARD9 binding did not affect Rubicon’s ability to suppress
autophagosome maturation: similar to Rubicon WT, expression
of the DSR-N or the DHC mutant, both capable of binding to
Beclin-1, increased LC3-II and p62 protein levels upon stimula-
tion with b-1,3-glucan or SeV, indicators of the autophagosome
maturation suppression (Figure 3D). These results indicate that
the Rubicon-CARD9 interaction specifically targets the CBM
complex to suppress the activation of NF-kB and p38/JNK
kinase activity without affecting CARD9-LyGDI complex
formation and CARD9-mediated ROS production, as well as
Rubicon-Beclin-1 complex formation and autophagosome
maturation inhibition.
Rubicon Has a Negative Effect on CBM-Mediated
Inflammatory Cytokine Production
Rubicon expressing Raw264.7 cells produced markedly lower
amounts of TNF-a and IL-6 than vector-containing control cells
(Figure 4A, Figures S4A and S4B). To further delineate Rubicon’s
actions in CBM-mediated proinflammatory cytokine production,
Raw264.7 and THP-1 cells expressing Rubicon mutants were
evaluated for their activities in comparison to cells expressing
WT upon various stimulations. Expression of the DSR-N, S284A,
DCCD, or DSR-C mutant suppressed proinflammatory cytokine
production as efficiently as WT, whereas expression of the
DHC mutant had no effect (Figure 4B and Figure S4C). Consis-
tently, lentivirus-mediated overexpression or shRNA-mediated
depletion of Rubicon in mouse BMDMs or Raw264.7 cells sig-
nificantly decreased or increased TNF-a and IL-6 production
induced by b-1,3-glucan stimulation, respectively (Figures 4C
and 4D, Figures S4D and S4E). Additionally, BMDCs were in-
fected with recombinant adenoviruses (Ad-vector, Ad-Rubicon,
or Ad-shRubicon), followed by b-1,3-glucan stimulation or SeV
infection. This too showed that Rubicon expression markedly
suppressed TNF-a and IL-6 production, whereas Rubicon
depletion significantly enhanced it (Figure S4F). However,
Rubicon expression neither showed any detectable effect on
LPS (TLR4)- or CpG (TLR9)-stimulated cytokine productions in
Raw264.7 cells nor affected cytokine productions in CARD9/
BMDMs upon treatments with various stimuli including b-1,3-
glucan, heat-killed Candida albicans, or viral infections (Figures
S4G and S4H), indicating the specificity of Rubicon’s action in
Dectin1-CARD9-mediated signal transduction.
Rubicon Has a Negative Effect on Host Antifungal
Activity
Corresponding with the levels of proinflammatory cytokine pro-
duction, the viability and growth rate of intracellular C. albicans
were increased in Rubicon-expressing cells and decreased
in Rubicon-depleted cells compared to vector-containing
control cells (Figures 5A and 5B). Furthermore, the expressionst & Microbe 11, 277–289, March 15, 2012 ª2012 Elsevier Inc. 281
Figure 3. Rubicon Inhibits CBM-Mediated Signaling in a CARD9 Binding-Dependent Manner
(A) Rubicon expression suppresses b-1,3-glucan-induced downstream signaling. Raw264.7 cells containing vector, Rubicon, or its mutants were stimulated with
b-1,3-glucan for the indicated times and then subjected to IB analysis to detect the phosphorylated and total forms of p38, p42/p44 MAPK, JNK, or IkB-a.
(B) Rubicon expression levels show no effect on ROS production induced by Dectin-1-mediated stimulation. BMDMs infected with lentivirus-shRNA-NS or
lentivirus-shRNA-Rubicon for Rubicon depletion or infected with lenti-GFP or lenti-GFP-Rubicon for Rubicon expression were analyzed for ROS production upon
stimulation with b-1,3-glucan or zymosan depleted by hot alkali treatment (to remove its TLR-stimulating properties but keep its Dectin-1-stimulating activities), or
infection with SeV or VSV.
(C) Rubicon expression levels show no effect on CARD9-mediated ROS production. WT or CARD9 KO BMDMs infected with lenti-GFP or lenti-GFP-Rubicon for
Rubicon expression or infectedwith lentivirus-shRNA-NS or lentivirus-shRNA-Rubicon for Rubicon depletion were analyzed for ROSproduction upon stimulation
with zymosan, C. albicans, or influenza A virus infection. Values are the mean ± SD of triplicate samples. *p < 0.05 and **p < 0.01 compared with WT control
cultures.
(D) Rubicon suppresses autophagosome maturation. Raw246.7 cells expressing vector, Rubicon WT, DSR-N, or DHC mutant were treated with rapamycin,
starvation, b-1,3-glucan, or SeV infection for the indicated times, and their cell lysates were used for IB with aLC3, ap62, or aactin. See also Figure S3.
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of intracellular C. albicans as efficiently as that of WT, whereas
the expression of the DHC mutant showed no effects under
the same conditions (Figure 5B).
In order to assess whether the depletion or expression of
Rubicon affects in vivo host responses to C. albicans infection,
recombinant adenoviruses (Ad-vector, Ad-shRubicon, or Ad-
Rubicon) were injected intravenously via the tail vein twice and
subsequently challenged intravenously with a lethal C. albicans
dose (1 3 107 CFU per mouse) (Figures S5A and S5B). Mice
infected with Ad-vector showed a median survival of 8 days,282 Cell Host & Microbe 11, 277–289, March 15, 2012 ª2012 Elseviemice infected with Ad-Rubicon died detectably sooner (median
survival, 6 days), and mice infected with Ad-shRubicon showed
an increased survival rate (50% survival) (Figure 5C). To deter-
mine whether these effects were due to impaired and enhanced
fungal clearance in the Rubicon-expressing and Rubicon-
depleted mice, respectively, we measured the C. albicans loads
and serum cytokine levels in the liver, spleen, kidney, and lung at
4 days after infection with a lower C. albicans dose (13 106 CFU
per mouse). Under these conditions, Rubicon-expressing mice
and Rubicon-depleted mice had, respectively, 100-fold higher
and 50- to 100-fold lower C. albicans loads in those organsr Inc.
Figure 4. Negative Effect of Rubicon on Host Antifungal Immunity in a CARD9 Binding-Dependent Manner
(A) Decrease of Dectin-1 pathway-induced cytokine productions by Rubicon. Raw264.7 cells containing vector or Rubicon were stimulated with b-1,3-glucan for
ELISA. Additional data are shown in Figures S4A and S4B.
(B) Decrease of Dectin-1 pathway-induced cytokine productions by Rubicon. Raw264.7 cells and THP-1 cells containing vector, RubiconWT, or itsmutants were
stimulated with b-1,3-glucan or C. albicans infection for cytokine production by ELISA. Additional data are shown in Figure S4C.
(C) Rubicon expression decreases cytokine productions induced by b-1,3-glucan or zymosan depleted by hot alkali treatment. Raw264.7 cells and BMDMs
infected with lenti-GFP or lenti-GFP-Rubicon were stimulated with b-1,3-glucan or zymosan depleted by hot alkali treatment for cytokine ELISA.
(D) Depletion of Rubicon expression increases Dectin-1 pathway-induced cytokine productions. Raw264.7 cells and BMDMs lentivirus-shRNA-NS or lentivirus-
shRNA-Rubicon were stimulated with b-1,3-glucan or C. albicans infection for cytokine ELISA. The data are the mean ± SD of values from three experiments.
*p < 0.05; **p < 0.01; ***p < 0.001 compared with the control. See also Figure S4.
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with the C. albicans loads, the serum levels of TNF-a and IL-6
were lower in Rubicon-expressing mice and higher in Rubicon-
depleted mice than in mice infected with Ad-vector (Figure 5D).
To further investigate Rubicon’s effect on in vivo host
responses to C. albicans infection, we generated double trans-
genic mice SRA-rtTA/Flag-Rubicon that have both reverse
tetracycline transactivator (rtTA) under the control of macro-
phage-specific promoter, a modified human scavenger receptor
A (SRA) promoter (Puel et al., 2010), and Flag-tagged Rubicon
under the control of tetracycline-inducible promoter. Immuno-Cell Hoblot and confocal microscopy analyses of splenocytes isolated
from SRA-rtTA/Flag-Rubicon mice showed the macrophage-
specific, inducible expression of Rubicon (Figures S5C and
S5D). At 7 days posttreatment of doxycycline, mice were subse-
quently challenged intravenously with C. albicans (1 3 107 CFU
per mouse). Untreated SRA-rtTA/Flag-Rubicon mice showed
amedian survival of7 days with 40% survival rate, but doxycy-
cline-treated mice died noticeably sooner (median survival,
2 days) (Figure 5F). In addition, untreated mice had 100- to
300-fold lowerC. albicans loads in spleen and liver, respectively,
compared to doxycycline-treated mice (Figure 5G). Correlatedst & Microbe 11, 277–289, March 15, 2012 ª2012 Elsevier Inc. 283
Figure 5. Negative Effect of Rubicon on Host Antifungal Activity
(A) Rubicon expression suppresses intracellular fungal killing activity. Raw246.7 or BMDMs infected with lenti-GFP or lenti-GFP-Rubicon for Rubicon expression
or infected with lentivirus-shRNA-NS or lentivirus-shRNA-Rubicon for Rubicon depeletion were infected withC. albicans for the indicated times and then lysed to
determine intracellular C. albicans loads.
(B) Rubicon suppresses intracellular fungal killing activity in a CARD9-binding-dependent manner. Raw246.7 cells expressing vector, RubiconWT, or its mutants
were infected with C. albicans for the indicated times and then lysed to determine intracellular C. albicans loads.
(C–E) Alteration of Rubicon gene expression affects mouse mortality after C. albicans infection. At 48 hr postinjection with Ad-vector (1 3 1013 pfu/kg),
Ad-shRubicon (13 1012 pfu/kg), or Ad-Rubicon (13 1013 pfu/kg) twice i.v. via tail vein, micewere infectedwithC. albicans (13 107 CFU permouse), andmortality
was measured for n = 10 mice per group (C). Serum cytokine levels (D) or C. albicans loads of infected mice (n = 5 per group) in liver, spleen, kidney, and lung (E)
were determined at 4 days p.i. with C. albicans (1 3 106 CFU). Additional data including Rubicon expression in mice are shown in Figures S5A and S5B. CFU,
colony-forming units.
(F–I) Doxycycline-inducible, macrophage-specific Rubicon expression affects mouse mortality after C. albicans infection. After 7 days of doxycycline treatment,
SRA-rtTA/Flag-Rubicon double transgenicmice were infected withC. albicans (13 107 CFU permouse), andmortality wasmeasured for n = 6mice per group (F).
C. albicans loads of infected mice (n = 6 per group) in liver and spleen (G), serum cytokine levels (H), and H&E staining of spleens (I) were determined at 4 days p.i.
with C. albicans (13 106 CFU). Additional data including Rubicon expression in mice are shown in Figures S5C–S5E. The data are the mean ± SD of values from
three experiments. *p < 0.05; **p < 0.01; ***p < 0.001 compared with the control. Scale bars, 200 mm. See also Figure S5.
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serum TNF-a and IL-6 levels and more severe infection-induced
splenomegaly and inflammation than doxycycline-treated mice284 Cell Host & Microbe 11, 277–289, March 15, 2012 ª2012 Elsevie(Figures 5H and 5I and Figure S5E). These results unambiguously
show that host defenses against fungal infection are substan-
tially affected by the levels of Rubicon expression.r Inc.
Figure 6. Negative Effect of Rubicon on Host Antiviral Activity
(A) Decrease of virus infection-induced cytokine production by Rubicon. Raw264.7 cells containing vector, Rubicon WT, or its mutants were infected with
influenza A virus PR8, SeV, or GFP-VSV for cytokine ELISA. Additional data of THP-1 cells are shown in Figures S6C.
(B) Rubicon expression levels affect virus infection-induced cytokine production. Raw264.7 cells and BMDMs infected with lenti-GFP or lenti-GFP-Rubicon for
Rubicon expression or infected with lentivirus-shRNA-NS or lentivirus-shRNA-Rubicon for Rubicon depeletion were infected with SeV or VSV for cytokine ELISA.
Additional data are shown in Figures S6D and S6E.
(C) Rubicon expression levels affect intracellular virus-killing activity. Raw246.7 or BMDMs infected with lenti-GFP or lenti-GFP-Rubicon for Rubicon expression
or infected with lentivirus-shRNA-NS or lentivirus-shRNA-Rubicon for Rubicon depeletion were infected with VSV for the indicated times, the culturemediumwas
harvested, and virus loads were determined by plaque assay on Vero cells. Additional data are shown in Figures S6F and S6G.
(D) Rubicon expression suppresses intracellular virus-killing activity in a CARD9-binding-dependent manner. Raw246.7 cells expressing vector, Rubicon WT, or
its mutants were infected with influenza A virus PR8 strain or VSV at various mois for the indicated times, and virus loads were determined by plaque assay on
MDCK or Vero cells, respectively. Additional data are shown in Figure S6H.
(E and F) Alteration of Rubicon gene expression affectsmousemortality after influenza A virus infection. At 48 hr postinjectionwith Ad-vector (13 1013 pfu/kg), Ad-
shRubicon (13 1012 pfu/kg), or Ad-Rubicon (13 1013 pfu/kg) twice i.v. via tail vein, mice were infected with influenza A virus PR8 strain (13 105 PFU per mouse)
andmortalitywasmeasured for n = 10mice per group (E). (F) Serumcytokine levels of infectedmice (n = 5 per group)were determined at 3 days p.i. with influenzaA
virus PR8 strain (53 104 PFU). Additional data including bodyweight loss and lung virus loads of the infectedmice are shown in Figures S6I and S6J. PFU, plaque-
forming units. The data are the mean ± SD of values from three experiments. *p < 0.05; **p < 0.01; ***p < 0.001 compared with the control. See also Figure S6.
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CARD9 also functions as an adaptor molecule to deliver the virus
infection-mediated intracellular RIG-I signaling (Poeck et al.,
2010). Rubicon expression markedly suppressed the phosphor-
ylation of p38, JNK, and IkB, and the degradation of IkB induced
by SeV infection (Figure S6A), and thereby led to significant
decreases in TNF-a, IL-6, and IL-1b production (Figures 6A
and 6B, Figures S6B–S6D). Conversely, the shRNA-mediated
depletion of endogenous Rubicon expression led to detectableCell Hoincreases of TNF-a, IL-6, and IL-1b production upon SeV
or vesicular stomatitis virus (VSV) infection (Figure 6B and
Figure S6E). Consistent with the inflammatory cytokine pro-
ductions, the replication rate of VSV was increased in Rubicon-
expressing cells and decreased in Rubicon-depleted cells
compared to vector-containing cells (Figure 6C, Figures S6F
and S6G). Furthermore, Raw264.7 or THP-1 cells stably ex-
pressing Rubicon mutants were evaluated for viral infection-
induced proinflammatory cytokine production. Expression ofst & Microbe 11, 277–289, March 15, 2012 ª2012 Elsevier Inc. 285
Figure 7. Hypothetical Model of Rubicon-Mediated Feedback Inhibition of CBM Signal Transduction
Please see the Discussion for detail.
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Rubicon-Mediated Inhibition of CARD9 Signalingthe DSR-N, S284A, DCCD, or DSR-C mutant suppressed proin-
flammatory cytokine production as efficiently as that of WT,
whereas expression of the DHC mutant showed no significant
effects (Figure 6A and Figure S6C). Correlated with their effects
on proinflammatory cytokine production, expression of the
Rubicon WT, DSR-N, and S284A mutants led to the increased
replications of influenza A virus A/PR/8/34 and VSV, whereas
expression of the DHC mutant showed no effects (Figure 6D
and Figure S6H).
In order to assess whether Rubicon expression levels affect
in vivo host responses to influenza A virus infection, a similar
approach to that described in Figure 5 utilizing recombinant
Rubicon adenoviruses was used, and mice were challenged
intranasally with a lethal dose of influenza A virus A/PR/8/34
strain (1 3 105 PFU per mouse). Mice infected with Ad-vector
showed rapid loss of weight and a median survival of 5 days,
mice infected with Ad-Rubicon lost weight faster and died de-
tectably sooner (median survival, 4 days), and mice infected
with Ad-shRubicon showed a noticeably delayed mortality rate
and increased survival rate (30% survival) (Figure 6E and Fig-
ure S6I). Rubicon-expressing mice and Rubicon-depleted mice
had, respectively, 100-fold higher and 100-fold lower virus
loads in their lungs compared to mice infected with Ad-vector
(Figure S6J). In correlation with the influenza A virus loads, the
serum levels of TNF-a and IL-6 were lower in Rubicon-express-
ing mice and higher in Rubicon-depleted mice than in mice in-
fected with Ad-vector (Figure 6F). Thus, host defenses against
viral infection are substantially affected by the levels of Rubicon
expression.
DISCUSSION
In this report, we present Rubicon as a specific feedback inhib-
itor of CARD9-mediated PRR-signal transduction, preventing
unbalanced proinflammatory responses.286 Cell Host & Microbe 11, 277–289, March 15, 2012 ª2012 ElsevieChanging Partners
Similar to its interaction with the Beclin-1 complex and the
NADPH oxidase complex upon autophagy and TLR stimulation,
respectively, Rubicon also changes its binding partners from
14-3-3b to CARD9 in a Dectin-1- or RIG-I-stimulation-depen-
dent, competitive manner, thereby disassembling the CBM
signaling complex and ultimately stopping PRR-induced inflam-
matory cytokine production. The obvious question is what types
of molecular mechanisms specifically induce Rubicon’s transfer
from 14-3-3b binding to CARD9 binding. Rubicon contains two
serine-rich regions, SR-N and SR-C, in its central region that
appear to be responsible for ‘‘latent’’ binding to 14-3-3b and
‘‘inducible’’ binding to p22phox, respectively. Indeed, the
specific deletion (DSR-N) or point mutation (S248A) of Rubicon
completely abolished its interaction with 14-3-3b (Figures 1B
and 1C). Based on these, we hypothesize that Rubicon’s
interaction with 14-3-3b, which occurs constitutively and
during the initial period of stimulation, sterically hinders a
CARD9 interaction, permitting CBM signal transduction, NF-kB
activation, and proinflammatory cytokine production (Figure 7).
At the late stage of signaling, however, Rubicon may lose
S248-phosphorylation, dissociating from14-3-3b to allowa stable
but transient interaction with CARD9, thus disassembling the
CBM signaling module and thereby terminating PRR-mediated
proinflammatory cytokine production (Figure 7). However, it is
also possible that Rubicon interaction with 14-3-3b may result
in the recruitment of other proteins and/or alteration in its subcel-
lular localization, which prevents the interaction with CARD9.
Nevertheless, by changing partners between 14-3-3b and
CARD9 in a specific-stimulation- and time-dependent manner,
Rubicon functions as the regulatory ‘‘off’’ switch of Dectin-1-
and RIG-I-mediated inflammatory signal transduction in this
model.
Several of the data presented here support our hypothesis.
First, Rubicon’s interaction with 14-3-3b was initially evidentr Inc.
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stimulation. By striking contrast, Rubicon interaction with
CARD9 was undetectable during the initial 30 min of stimula-
tion, but robustly increased after 30–60 min of stimulation,
and then declined thereafter (Figures 2A and 2B and Fig-
ure S2A). These features are also binding specific: the DSR-N
and S284A mutants that lost 14-3-3b interaction continuously
bound CARD9 with no b-1,3-glucan stimulation conditions,
and the DHC mutant that lost CARD9 interaction continu-
ously associated with 14-3-3b regardless of b-1,3-glucan stim-
ulation. Second, as seen with Rubicon, CARD9 also shows
differential binding partners and kinetics: it associates with
BCL10 without stimulation, with these interactions detectably
increasing at 15 min of b-1,3-glucan stimulation but drastically
decreasing thereafter (Figure S2D). Contrastingly, the CARD9-
Rubicon interaction is initially minimal, but markedly increases
after 30–60 min of b-1,3-glucan stimulation and declines after-
ward (Figure S2D). Third, the unique binding partners and
kinetics of both Rubicon and CARD9 are also stimulation
specific for only b-1,3-glucan stimulation or SeV infection, as
neither rapamycin nor zymosan stimulation modified their
interactions. These results collectively demonstrate that
Rubicon dynamically changes binding partners from 14-3-3b
to CARD9 in a specific-stimulation-dependent, competitive
manner.
Inhibitory Feedback Regulation of CARD9 Signaling
Positive and negative regulatory mechanisms are required to
maintainmost biological processes at equilibrium.While a robust
antimicrobial response induced by the PRR pathway is essential
for controling microbial infection, this responsemust bemetered
and eventually eliminatedwhen it reaches a late stage, to prevent
damage from the excessive production of inflammatory cyto-
kines. Since CARD9 is a central molecule for transducing signals
frommultiple PRRs to induce immunity to various pathogens, it is
important to understand how the deregulation of CARD9
signaling might contribute to immune cell-mediated diseases.
Loss-of-function mutations in the CARD9 gene causes suscep-
tibility to infections, as CARD9/ mice are highly vulnerable to
fungal and bacterial pathogen infections (Hsu et al., 2007; Ru-
land, 2008; Werninghaus et al., 2009; Wu et al., 2009). Further-
more, a CARD9 mutation in humans is associated with an
increased susceptibility to chronic mucocutaneous candidiasis
(Glocker et al., 2009). On the other hand, aberrant activation of
CARD9, either through genetic mutations or via environmental
factors, may result in pathological immune cell activation,
causing inflammatory diseases or certain cancers (Ruland,
2008). For instance, a single CARD9 nucleotide polymorphism
is associated with inflammatory bowel disease (Zhernakova
et al., 2008), and CARD9 overexpression is found in gastric B
cell lymphoma specimens (Zhernakova et al., 2008; Zhou
et al., 2006). To avoid aberrant activation of CARD9 signaling
activity and excessive production of inflammatory cytokines,
the host immune system employs Rubicon to target 14-3-3b
and CARD9 in a specific-stimulation-dependent manner, in
order to disassemble and halt CBM complex-mediated signaling
activity. Thus, Rubicon serves as an inhibitory feedback regu-
lator of CBM-mediated immune responses by acting as a physi-
ological brake.Cell HoRubicon’s Roles in Autophagy-, Phagocytosis-,
and PRR-Mediated Signal Transduction
The initial innate immunity mechanisms of autophagy, phagocy-
tosis, and PRRs have been shown to efficiently collaborate to
generate effective host responses against microbial infections
(Kumar et al., 2011; Palm and Medzhitov, 2009; Reid et al.,
2009). As seen in the cooperation between PRRs and phagocy-
tosis and between PRRs and autophagy, phagocytosis and
autophagy also collaborate as part of the host’s first line of
immune defense againstmicrobial invasions (Deretic and Levine,
2009). Specifically, autophagy facilitates phagocytosis by
promoting phagosome maturation and rapid acidification, and
by preventing pathogens from escaping into the cytosol (Huang
et al., 2009; Sanjuan et al., 2007; Tal et al., 2009; Travassos et al.,
2010; Virgin and Levine, 2009). While Rubicon was initially iden-
tified as an autophagy gatekeeper, it is involved in three different
ancient innate immune machineries, autophagy, phagocytosis,
and PRRs, by targeting them depending on the environmental
stimuli and ultimately generating an intracellular immune milieu
against microbial infection. To efficiently do this, Rubicon
acts on the Beclin-1-containing autophagy complex, on the
NADPH-oxidase-containing phagocytosis complex, and on
the CARD9-containing signaling complex in a functionally and
genetically separable manner. Although the precise contribu-
tions of Rubicon to the control of host immunity are only
beginning to be defined, it is clear that Rubicon is an important
regulator of innate immune responses against various microbial
infections.EXPERIMENTAL PROCEDURES
Yeast Two-Hybrid Screen
Yeast transformation with library cDNA was performed as recommended by
the manufacturers.
Briefly, yeast strain Y187 bearing Gal4-Rubicon full-length or Gal4-
N-terminal region (aa 1–505), or Gal4-C-terminal region (aa 506–972) plasmid,
was grown overnight in synthetic dropout (SD)/-Trp medium to a density of
approximately 107 cells/ml, then diluted in 1 l of warmed YPD to an optical
density (OD600) of 0.2–0.3 and grown to exponential stage. Cells were har-
vested and washed with 100 ml of water twice and TE buffer once. The pellets
were resuspended in 8 ml of 10 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.1 M
Li-acetate (LiOAc), and the suspension was mixed with 1 mg of transforming
DNA and 20 mg of single-stranded salmon sperm DNA, after which 60 ml of
a solution of 40% polyethyleneglycol-4000 in Tris-EDTA-LiOAc was added
and mixed thoroughly, followed by incubation at 30C with agitation for
30 min. After a heat pulse at 42C for 15 min, cells were pelleted, washed
with 50 ml of Tris-EDTA, and plated on selective medium. Library screening
and recovery of plasmids were performed according to the manufacturer’s
instructions (Clontech).
Quantification of C. albicans Growth
To ensure the reliable quantification of intracellular yeast cells, colony-forming
units (CFUs) were utilized. Cells were infected for 2 hr with C. albicans at
different mois. Then cells were washed three times with PBS, and fresh
medium was added. After various periods of incubation, cells were lysed
with 0.3% saponin to release the intracellular yeast cells, and the lysates of
infected cells were then resuspended vigorously, transferred to screw-cap-
ped tubes, and sonicated in a preheated 30C water bath sonicator (Elma)
for 5 min. Aliquots of the sonicates were then diluted 10-fold in YPD broth
medium. Four dilutions of each sample were plated separately on YPD agar
plates and incubated at 30C with 5% CO2 for 1 day. CFU was counted,
and the intracellular yeast cells were calculated in comparison with CFU of
yeast grown in the same conditions without cells. For statistical reasons,st & Microbe 11, 277–289, March 15, 2012 ª2012 Elsevier Inc. 287
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the titer.
Quantification of VSV or Influenza A Virus Growth
The titer or concentration of infectious virus particles in solution or cell culture
mediumwas determined by plaque assay. For VSV, Vero cells were grown until
a monolayer of cells was formed. Serially diluted virus solution (0.1 ml) was
added to each well and incubated for 1 hr at RT in a rocker. Virus solutions
were then removed, and cells were covered with overlay medium (1:1 mixture
of 1.5% methyl cellulose agar and MEM without FBS). After 5 min, mixtures
were solidified and placed in a 37C incubator for 24–36 hr.
For influenza A virus, MDCK cell monolayers were inoculated with 0.1 ml of
virus appropriately diluted in PBS supplemented with 0.2% bovine serum
albumin for 60 min at room temperature. At the completion of the 60 min incu-
bation, cells were mixed the 2% Oxoid agar with the remaining premixed
components of the agar overlay (23 MEM without FBS, 1% DEAE dextran,
5% NaHCO3, 1 mg/ml trypsin-TPCK) and incubated for at least 3 days, or until
virus plaques were clearly visible. Then crystal violet stain was added to each
well and incubated overnight at RT for counting plagues, and the titer of the
solution was calculated.
Production of Lentiviral shRubicon or Rubicon
For silencing of human Rubicon, oligonucleotide sequences for shRNA inter-
ference with Rubicon expression are bp 513–536 of 50-GAUCGAUGCGUC
CAUGUUU-30, followed by a 9 nt noncomplementary spacer (TTCAAGAGA)
and the reverse complement of the initial 19 nt sequence. These dsDNA oligo-
nucleotides were cloned into the pGIPZ lentiviral vector (Open Biosystems).
Lentiviruses were produced by transient transfection using packaging plas-
mids (psPAX2 and pMD2.VSV-G purchased from Addgene) after Lipofect-
amine 2000 mediated transient transfection into 293T cells. Control vector
was constructed by inserting sequences with limited homology to the Rubicon
sequences. DNA fragments corresponding to the coding sequences of the
Rubicon genes were amplified by PCR and subcloned into pCDH-CMV vector
(System Biosciences).
Transduction of Lentiviral shRubicon or Rubicon
Viral-containingmedia were collected 72 hr posttransfection and harvested for
the viral particles by passing the supernatants through a 0.45 mm filter. The
supernatants were used to infect 23 105 cells in 6-well plates in the presence
of 8 mg/ml Polybrene. For lentivirus infection, cells (53 105 cells/ml) in DMEM+
10% FBS were seeded in 24-well plates. After 24 hr, cells were infected with
lentiviral vectors at various mois in the presence of 8 mg/ml Polybrene. On
the following day, the medium was freshly replaced, and cells were incubated
for additional 4 days for Rubicon knockdown. A parallel experiment using
a GFP encoding lentivirus indicated that a minimum of 80% of Raw264.7
and BMDMs cells were transduced by lentiviruses. Titration of the lentiviral
vectors was determined using 293T cells. Briefly, approximately 2 3 105 cells
were plated in each well of a 6-well plate. On the following day, cells were in-
fected with viral supernatants in the presence of 8 mg/ml Polybrene. After 24 hr,
medium was removed and replaced with fresh medium containing 5 mg/ml
puromycin. On day 14, cells were stained with crystal violet for 15 min, and
colonies were counted using a cutoff of 50 viable cells.
Construction of Adenoviral shRubicon or Rubicon
An adenovirus expressing short hairpin RNA (shRNA) to the Rubicon gene
was constructed using the AdEasy system (Stategene). The shRNAoligonucle-
otides sequences were as follows: 50-GATCCCCGATAGACAGTATATC
AGAATTCAAGAGATTCTGATATACTGTCTATCTTTTTA-30, 50-GGGCTATCTG
TCATATAGTCTTAAGTTCTCTAAGACTATATGACAGATAGAAAAATTCGA-30.
These dsDNA oligonucleotides were cloned into the pSuper vector between
the BglII and HindIII restriction sites containing the human H1 promoter. The
double-strand shRNA oligonucleotides containing the termination signal
were inserted at the 30 end of the human H1 promoter and subcloned into
the pShuttle vector NotI and HindIII restriction sites. Control vector was con-
structed by inserting a sequence that expresses an shRNA with limited
homology to the Rubicon sequences. DNA fragments corresponding to the
coding sequences of theRubicon geneswere amplified byPCRand subcloned
into the pShuttle-CMV vector between the NotI and EcoRV restriction sites.288 Cell Host & Microbe 11, 277–289, March 15, 2012 ª2012 ElsevieAdenovirus Production
Recombinant adenoviruses were constructed using AdEasy system: digested
adenovirus vectors with the Pac I were transfected into the AD-293 producer
cells in a 6-well plate and cultured with fresh media until cytopathic effect was
observed. When 80% CPE were observed, recombinant adenoviruses were
harvested by repeatedly freezing at –80C and thawing at 37C four times.
Cell lysates were then centrifuged at 2000 g for 30 min at 25C, and the
supernatants containing recombinant adenovirus particles were stored
at –80C.
All adenoviruses were propagated in AD-293 cells, purified, and concen-
trated by BD Adeno-X purification kit. The typical titers were in the range of
1012–1013 plaque-forming units (pfu)/mL as determined via plaque assay using
1.25% SeaPlaque GTG agarose (BioWhittaker Molecular Applications) over-
lay. A sterile carrier solution phosphate-buffered saline was used for control
injections and dilution of the viruses.
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